13321_2015_108_MOESM1_ESM.docx Additional file 1: Brief description of the evaluated fingerprints.
Please refer to Tables 1, 2, and 3 for the description of the evaluated parameters.
Table 1 Description of initiators evaluated Initiators Abbreviation Structural formula Molecular weight Camphorquinone CQ 166.22 (7-ethoxy-4-methylcoumarin-3-yl) phenyliodonium hexafluoroantimonate P3C-Sb 627.39 Ethyl 4-dimethylaminobenzoate EDAB 193.24.
From selected trials, the following data were extracted: name of the first author, year of publication, country(ies) where the study was conducted, number of participants, description of disease evaluated according to groups of global burden of disease and type of funding.
Also, qualitative considerations and a quantitative description to evaluate feasibility of new drug delivery strategies are provided, and some indicators, such as the emptying time, useful to optimize the drug-eluting stent design are discussed.
A systematic review of exercise trials for chronic conditions reported suboptimal descriptions of the evaluated interventions and concluded that this hinders interpretation and replication.
The accuracy of this description was evaluated through comparison of derived and directly measured aerosol properties including mass, absorption coefficient, hemispherical backscattering coefficient, and total scattering coefficient at two different relative humidities.
In Section 2 there is a brief description of the background, followed, in Section 3, with a detailed description of the method of evaluating quality adjustment indices.
Additional file 1: Description of data: Questionnaire evaluated in the study.
This theoretical description is evaluated on the basis of systematic comparison with experimental data obtained under steady flow or unsteady (oscillating) flow without and with moving vocal folds.
